Vasopressors for cardiopulmonary resuscitation. Does pharmacological evidence support clinical practice? by Penson, P et al.
- 1 - 
   
 
Vasopressors for cardiopulmonary 
resuscitation. 
Does pharmacological evidence support clinical practice? 
 
 
 
 
 
Peter E. Penson, William R. Ford and Kenneth J. Broadley 
Division of Pharmacology, Welsh School of Pharmacy, Cardiff University, King  
Edward VIII Avenue, Cathays Park, Cardiff, CF10 3NB, UK 
 
 
 
 
 
Corresponding author. Tel.: +44-29-20-875832; fax +44-29-20-874149 
E-mail address: BroadleyKJ@Cardiff.ac.uk. (K.J.Broadley) 
 
 
- 2 - 
   
 
Contents 
1 Introduction ..................................................... 7 
1.1 Historical aspects ........................................................................................... 7 
1.2 Current clinical practice ................................................................................. 7 
1.3 Mechanism of action of chest compressions in CPR ..................................... 9 
1.4 Rationale for the use of adrenaline in CPR .................................................... 9 
2 Pathophysiology of cardiac arrest and 
ischaemic damage to the heart. ......................... 12 
2.1 Time course of cardiac arrest ....................................................................... 12 
2.2 Overview of ischaemic damage and reperfusion injury .............................. 14 
3 Pharmacodynamic and pharmacokinetic 
properties of adrenaline. .................................... 15 
3.1 Pharmacology of adrenaline relevant to CPR .............................................. 16 
3.1.1 Actions on vascular adrenoceptors ...................................................... 17 
3.1.2 Action on cardiac adrenoceptors. ......................................................... 20 
3.1.3 Vasopressors after ROSC. ................................................................... 21 
3.2 Miscellaneous properties of adrenaline relevant to resuscitation ................ 21 
3.2.1 Coronary vasoconstriction ................................................................... 21 
3.2.2 Platelet aggregation .............................................................................. 22 
3.2.3 Oxidation of catecholamines ................................................................ 22 
- 3 - 
   
3.2.4 Adrenoceptor desensitisation ............................................................... 23 
3.2.5 Interactions with drugs concomitantly taken by patients. .................... 24 
3.2.6 Consequences of exposure to adrenaline at reperfusion ...................... 24 
3.2.7 Hypokalaemia induced by β-adrenoceptor activation.......................... 25 
3.2.8 Pulmonary ventilation/perfusion mismatching .................................... 25 
3.2.9 Distribution of adrenaline. ................................................................... 26 
3.2.10 Effects of adrenaline on mast cells ...................................................... 26 
4 Possible alternatives to the use of adrenaline
 27 
4.1 Selective α-adrenoceptor agonists ............................................................... 27 
4.2 Directing endogenous and administered adrenaline towards α2- 
adrenoceptors with antagonists. ............................................................................... 29 
4.3 Non adrenergic vasopressor agents. ............................................................. 30 
4.4 Ideal properties of resuscitation vasopressor ............................................... 31 
4.5 General effects of vasopressors which may limit usefulness during 
resuscitation ............................................................................................................. 32 
5 Experimental models ..................................... 33 
5.1 In vivo experiments...................................................................................... 34 
5.2 In vitro isolated organs and cell culture methods ........................................ 35 
5.3 Cardioactive properties of agents used in experimental models .................. 36 
5.4 Why are models a poor representation of the clinical situation? ................. 37 
6 Clinical evidence ............................................ 38 
6.1 Comparison of standard-dose adrenaline and placebo ................................. 40 
- 4 - 
   
6.2 High-dose adrenaline ................................................................................... 42 
6.3 Other Adrenergic agents .............................................................................. 47 
6.4 Non adrenergic vasopressors ....................................................................... 48 
6.5 Vasopressor combinations ........................................................................... 49 
6.6 Conclusions from clinical trials ................................................................... 50 
7 Conclusions .................................................... 51 
Acknowledgement .............................................. 54 
Figures and Tables ............................................. 65 
 
- 5 - 
   
Abstract 
 
Adrenaline (epinephrine) has been used for cardiopulmonary resuscitation since 1896; 
the rationale behind its use is thought to be its α-adrenoceptor-mediated peripheral 
vasoconstriction, causing residual blood-flow to be diverted to coronary and cerebral 
circulations. This protects these tissues from ischaemic damage and increases the 
likelihood of restoration of spontaneous circulation. Clinical trials have not 
demonstrated any benefit of adrenaline over placebo as an agent for resuscitation. 
Adrenaline has deleterious effects in the setting of resuscitation, predictable from its 
promiscuous pharmacological profile. This article discusses the relevant 
pharmacology of adrenaline in the context of cardiopulmonary resuscitation. 
Experimental and clinical evidence for the use of adrenaline and alternative 
vasopressor agents in resuscitation is given, and the properties of an ideal vasopressor 
are discussed. 
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1 Introduction  
1.1 Historical aspects 
 
Cardiac arrest is the ultimate medical emergency and resuscitation has occupied the 
minds of people throughout the ages. History records numerous bizarre and probably 
unhelpful resuscitation techniques. These included rolling the victim around on top of 
a barrel or pumping tobacco smoke into his rectum (Hermreck 1988). Artificial 
ventilation was first attempted in the 16th century, and electrical defibrillation was 
initially investigated in the 18th. Cardiac massage and the use of adrenal gland extract, 
were both innovations of the 19th century (Hermreck 1988). Although myocardial 
infarction is the most common cause of cardiac arrest, it has been estimated that 
between 10% and 34% of cardiac arrests presenting in hospital are of non-cardiac 
origin (Grubb et al. 1995; Fischer et al. 1997; Kuisma and Alaspaa 1997; Weston et 
al. 1997; Engdahl et al. 2003). Commonly occurring non-cardiac causes of cardiac 
arrest include haemorrhage, trauma, pulmonary embolism, near drowning and 
intoxication (Kuisma and Alaspaa 1997). Cardiac arrest can also be precipitated by 
electrolyte abnormalities, sepsis (Hess et al. 2007) electrocution (Beers and Berkow 
1999a) and iatrogenic effects (Brembilla-Perrot et al. 2003).  
 
1.2 Current clinical practice 
In order to achieve successful resuscitation and to prevent damage to the vital organs 
(in particular the heart and the brain), blood-flow must be rapidly restored to allow 
these vulnerable tissues to be reperfused. The International Liaison Committee on 
Resuscitation has issued guidelines for ‘Advanced Cardiac Life Support’. They 
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suggest the use of adrenaline (epinephrine) in the treatment of all major types of 
rhythm disturbances presenting with cardiac arrest (International Liaison Committee 
on Resuscitation 2005). This includes the so called ‘shockable’ rhythms (ventricular 
fibrillation and pulseless ventricular tachycardia) which are treated with 
cardiopulmonary resuscitation (CPR) (ventilation and chest compressions) 
interspersed with defibrillator shocks, designed to restore the normal cardiac rhythm 
and adrenaline. ‘Non shockable’ rhythms (asystole and pulseless electrical activity) 
should also be treated using CPR and adrenaline. As the name suggests, defibrillation 
is not used as treatment for these rhythms. The distribution of the adrenaline around 
the circulatory system is achieved by the closed-chest cardiac massage element of 
CPR (International Liaison Committee on Resuscitation 2005) (Figure 1).  
 
In Britain, it is recommended that 1mg of adrenaline should be given intravenously 
every three minutes during cardiac arrest (Mehta 2006) although international 
guidelines suggest dosing every three to five minutes (International Liaison 
Committee on Resuscitation 2005). This disparity probably reflects the fact that the 
guidelines are based on best practice and collective wisdom rather than evidence 
based medicine. Adrenal gland extract was first used for the purpose of resuscitation 
in 1896 (Gottlieb 1896; Crile and Dolley 1906) and adrenaline was used clinically 
initially as an intracardiac injection (Pearson and Redding 1963; Pearson and Redding 
1964a) and subsequently as an injection into a peripheral vein followed by a saline 
flush and continuing chest compressions (Mehta 2006).  
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1.3 Mechanism of action of chest compressions in CPR 
In order to aid recovery of a patient in cardiac arrest and to ensure perfusion of the 
vital organs, some method of ensuring a degree of circulation is required. This is 
achieved by repeated manual compressions of the chest. There are two (not mutually 
exclusive) theories as to how chest compressions lead to circulation of the blood. The 
‘thoracic pump’ theory reasons that the intrathoracic pressure generated by chest 
compressions drives blood from the thorax into the general circulation, venous valves 
prevent backflow of blood, and thus repeated compressions can pump the blood 
around the circulation. The increased intrathoracic pressure would also assist venous 
return into the ventricles by compressing the vena thoracic vena cava and pulmonary 
vein. The ‘cardiac pump’ theory assumes that compression of the ventricles causes 
closure of the atrioventricular valves, and ejection of blood into the pulmonary artery 
and aorta. This has been extensively reviewed elsewhere (Andreka and Frenneaux 
2006). It is important to note that distribution of any drug injected into the circulatory 
system during cardiac arrest is dependent upon, and limited by the blood-flow 
generated by CPR.  
 
1.4 Rationale for the use of adrenaline in CPR 
Interestingly, although the recommendations for the administration of adrenaline to a 
patient in cardiopulmonary arrest have changed little over the past century, the 
supposed rationale for the use of adrenaline have altered more than once. Crile and 
Dolley (1906) are quite clear about “The value of adrenalin in raising the blood pressure, by 
its action upon the vascular walls in the state of suspended animation”. However, Pearson and 
Redding cite the coronary arteries as the site of action (Pearson and Redding 1963) 
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and later it is suggested that the benefit of adrenaline lies in it increasing the 
amplitude of fibrillation and associated contractions prior to the application of a 
defibrillating electric current (Livesay et al. 1978). Studies in dogs carried out in the 
1980s have led to the currently held view that peripheral arteriolar vasoconstrictor 
effects of adrenaline account for any beneficial effects seen at resuscitation. 
Constriction of peripheral circulation ensures that blood-flow generated by CPR is 
thus directed to coronary and cerebral circulation. Vasopressors are thought to prevent 
arterial collapse as intrathoracic pressure is raised by chest compressions (Michael et 
al. 1984). Aortic diastolic pressure, an important determinant of coronary blood-flow 
is increased (Michael et al. 1984; Brown and Werman 1990). Maintenance of 
coronary blood-flow is the most important factor in enabling return of spontaneous 
circulation (ROSC) or successful defibrillation (Kern et al. 1988; Paradis et al. 1990; 
Paradis et al. 1991; Babbs et al. 2001; Zhong and Dorian 2005)  
 
It is interesting to note that one historical resuscitation method was to throw cold 
water at the face of the victim. (Hermreck 1988). History does not record the 
effectiveness of this technique, however it may have activated the human dive reflex 
which causes bradycardia and peripheral vasoconstriction (Levick 2003) 
 
The peripheral vasoconstrictor effects of adrenaline are as a result of the activation of 
α-adrenoceptors, particularly in arterioles in the kidney, mucosa and skin and also in 
many veins (Hoffman 2001; Hoffman and Taylor 2001). The receptor subtypes 
involved will be discussed below in section 3.1.1. Catecholamines such as adrenaline 
do not penetrate the blood-brain-barrier (Dahlgren et al. 1980) and cannot act on 
central adrenoceptors when given systemically. Changes in systemic blood pressure, 
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therefore, largely dictate alterations in cerebral blood flow (Dahlgren et al. 1980; 
Hoffman 2001). Thus, the increased blood pressure achieved by peripheral 
vasoconstriction improves blood-flow in the coronary and cerebral circulations, 
protecting the most vital organs from ischaemic damage and improving the chances of 
achieving ROSC.  
 
Despite its widespread use, a large body of experimental evidence from animal 
studies suggests that adrenaline may have no effect or even a detrimental effect on 
various measures of well-being and survival during resuscitation (Brown et al. 1988; 
Wenzel et al. 1999; Klouche et al. 2003; Niemann and Garner 2005; Schwartz and 
Lagranha 2006) . High doses do not seem to improve survival and may increase 
adverse effects (Ditchey and Lindenfeld 1988; Lindner et al. 1991b; Lindner et al. 
1991a; Hornchen et al. 1993; Hilwig et al. 2000; Voelckel et al. 2000). These 
concerns have been upheld by the results of several clinical trials (Marwick et al. 
1988; Olson et al. 1989; Herlitz et al. 1995; Woodhouse et al. 1995; Sherman et al. 
1997; Behringer et al. 1998; Holmberg et al. 2002). See section 6 below. The most 
recent international guidelines, issued in 2005 concluded: 
 
“Despite the widespread use of adrenaline during resuscitation, and several studies 
involving vasopressin, there is no placebo-controlled study that shows that the routine 
use of any vasopressor at any stage during human cardiac arrest increases survival to 
hospital discharge. Current evidence is insufficient to support or refute the routine 
use of any particular drug or sequence of drugs. Despite the lack of human data, the 
use of adrenaline is still recommended, based largely on animal data.” 
(International Liaison Committee on Resuscitation 2005). 
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This paper will review the evidence for and against the use of adrenaline for 
resuscitation. The focus will be on the pharmacological basis for the use of various 
agents and how this translates into success in the clinical setting. Often, agents which 
show promise experimentally yield disappointing results in the clinic. Experimental 
models used in this field of research are briefly described and their strengths and 
weaknesses discussed. The results of clinical trials in resuscitation are then discussed 
in detail.  
 
2 Pathophysiology of cardiac arrest and ischaemic 
damage to the heart. 
 
2.1 Time course of cardiac arrest 
 
In order to treat cardiac arrest effectively, the mechanism by which ischaemic damage 
progresses must be understood. Pearson and Redding (1964b) recognised the 
importance of the different requirements of treatment before and after ROSC. This is 
particularly interesting in the light of the discovery that after periods of ischaemia, 
tissues can be further damaged by reperfusion (Heyndrickx et al. 1975) and that the 
mechanisms of ischaemic damage to tissue are different from those of reperfusion 
injury (Carden and Granger 2000) (Figure 2). More recently a three-phase model of 
the pathophysiology which occurs during cardiac arrest has been suggested (Weisfeldt 
and Becker 2002). This model divides the pathophysiology and treatment of cardiac 
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arrest into the following phases: (1) the electrical phase (up to four minutes after the 
cardiac arrest begins); (2) the circulatory phase (from four to ten minutes); and (3) the 
metabolic phase (after 10 minutes). According to the model, electrical defibrillation is 
most successful during the electrical phase and should be attempted if possible. If 
treatment is not begun until the circulatory phase, then interventions designed to 
supply oxygen to the vital organs (such as chest comprssions, artificial ventilation and 
vasopressor administration) should be carried out prior to attempted defibrillation. If 
treatment is not initiated until the metabolic phase has begun, chances of survival are 
poor. During this phase, gut bacteria release endotoxins into the circulatory system 
and if resuscitation is successful, severe reperfusion damage in all body tissues is 
likely (Weisfeldt and Becker 2002). It was suggested that adrenaline is most useful 
during the circulatory phase, where increases in coronary flow increase the likelihood 
of successful defibrillation. During the metabolic phase, the vasoconstriction elicited 
by adrenaline may cause ischaemia in various organs and therefore have a detrimental 
effect (Weisfeldt and Becker 2002).  
 
This model has important implications for the way in which cardiac arrest is treated. 
Currently, guidelines for the treatment of cardiac arrest do not make any reference to 
the length of ischaemia prior to treatment; however this model challenges the current 
approach. For instance, it seems likely that different requirements might apply when 
resuscitation takes place within a hospital (and access to a physician is presumably 
rapid) and out-of hospital resuscitation when there may be a delay in obtaining 
medical assistance. Of interest, one clinical trial including 650 patients noted poor 
rates of survival when a high dose of adrenaline was given later than 10 minutes after 
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cardiac arrest (Stiell et al. 1992). Further analysis of time-course data is required to 
determine the significance of such observations. 
 
2.2 Overview of ischaemic damage and reperfusion injury 
Ischaemia plays a dual role in cardiac arrest; because the heart is a pump which 
supplies blood to all parts of the body (including itself, via the coronary artery), 
myocardial ischaemia inevitably occurs during sudden cardiac death and other 
immediate causes of cardiac arrest. However, myocardial ischaemia and infarction are 
also the most common causes of cardiac arrest (Camm 2002). Infarction follows 
thrombus formation in a coronary artery leading to ischaemic damage of the 
myocardium, infarct formation and subsequent electromechanical dysfunction (Beers 
and Berkow 1999c). 
 
Rapid reperfusion of the tissue in question has traditionally been the treatment for 
ischaemia, although it is now known that at reperfusion, damage occurs over and 
above that sustained during ischaemia. This discovery led to the concept of 
‘reperfusion injury’ (Braunwald and Kloner 1985). The paradox that reperfusion is 
both necessary for survival and damaging has lead to it being described as a ‘double-
edged sword’(Braunwald and Kloner 1985). Reperfusion injury is an important 
consideration from a clinical perspective because whilst it is almost impossible to 
predict when cardiac arrest will occur, reperfusion can happen as a result of a medical 
intervention (e.g. defibrillation and thrombolysis) and therefore is more amenable to 
therapeutic interventions (Piper et al. 2004). Various pharmacological agents 
including adenosine and opioids have been demonstrated to attenuate reperfusion 
injury in animal models. This has been extensively reviewed by Gross and Gross 
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(2006). Such agents have the potential to be administered at the time of defibrillation 
or thrombolysis, in order to minimise the damaged caused by reperfusion. Thus, if it 
is to be of use as a model for advancing clinical treatments of cardiac arrest, a 
reperfusion phase would be a useful addition to the three-phase model of Weisfeldt & 
Becker (2002). 
 
Cardiac arrest can be associated with numerous presenting rhythms. Ventricular 
fibrillation is the most common presenting rhythm, occurring in 70% of cases of 
cardiac arrest. Co-ordination of cardiac contraction is lost and cardiac output is 
negligible. Pulseless electrical activity (also known as electromechanical dissociation 
or non-perfusing rhythm) refers to a situation whereby the pattern of electrical 
depolarisation within the heart is normal, but contraction does not occur. Asystole is 
an absence of both electrical and mechanical activity. (Beers and Berkow 1999c). 
 
The remainder of this review will discuss the relevant pharmacology of adrenaline 
and other vasopressors, and the consequences of administration of these agents during 
resuscitation from cardiac arrest.  
 
3 Pharmacodynamic and pharmacokinetic properties 
of adrenaline. 
 
Adrenaline is a non-selective α-and β-adrenoceptor agonist, released by the adrenal 
medulla in response to stress. The cardiovascular effects of adrenaline are complex 
due to the fact that several subtypes of adrenoceptors are present in the heart and in 
the vasculature and physiological responses are usually the result of a combination of 
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effects. Table 1 summarises some general features and indicates their relevance to 
CPR.  
 
The onset of myocardial ischaemia triggers the release of adrenaline from the adrenal 
medulla, as a result of fear and anxiety (if the patient is conscious) and the massive 
fall in blood pressure accompanying cardiac arrest (Schoemig and Richard 1991). An 
increase in sympathetic discharge also results in the release of noradrenaline from 
sympathetic neurones within the heart (Foley et al. 1987; Kern et al. 1989; Lindner et 
al. 1996a). In ischaemic regions, metabolic alterations during prolonged ischaemia 
lead to the emptying of neuronal noradrenaline vesicles into the cytoplasm. A reversal 
of the uptake transporter for noradrenaline releases the neurotransmitter into the 
synaptic cleft where it is able to accumulate. This noradrenaline release is 
independent of neuronal activity. Some synaptic noradrenaline spills over into the 
circulation. (Schoemig and Richard 1991). Hence cardiac arrest results in a raised 
plasma catecholamine state which is maintained long after resuscitation (Niemann and 
Garner 2005). The administration of adrenaline during cardiac arrest is therefore a 
mimic of the natural response, however high levels of endogenous catecholamines 
during CPR are correlated with poor survival (Lindner et al. 1996a) and to further 
increase concentrations may prove detrimental.  
 
3.1 Pharmacology of adrenaline relevant to CPR  
The introduction of adrenaline into the intact circulatory system of man causes an 
increase in cardiac output and blood pressure. This is brought about by constriction of 
arterioles, increase in venous return and by positive chronotropic and inotropic effects 
on the heart (Lichtenstein et al. 1987). Adrenaline causes vasodilatation by activation 
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of β2-adrenoceptors in the coronary artery, liver and skeletal muscle, but 
vasoconstriction (mediated by α-adrenoceptors) elsewhere (Ganong 2001). 
 
3.1.1 Actions on vascular adrenoceptors  
As described above, beneficial effects of adrenaline are thought to be mediated by 
peripheral vasoconstriction. Classically, in humans, α1-adrenoceptors are considered 
to be the main mediators of arteriolar vasoconstriction and α2-adrenoceptors whilst 
having a lesser role in arteriolar vasoconstriction, are important mediators of venous 
vasoconstriction. Contraction in response to neuronal action potentials in arterial 
smooth muscle is almost exclusively mediated by α1-adrenoceptors which are close to 
the sites of noradrenaline release at the synapse (Guimaraes and Moura 2001). 
Prejunctional α2-adrenoceptors are found on post-ganglionic sympathetic neurones. 
When activated by noradrenaline, they attenuate the further release of noradrenaline 
initiating a negative-feedback mechanism. However, α2-adrenoceptors are also 
present extrasynaptically, on smooth muscle cells and can contribute to 
vasoconstriction. The α2A subtype is probably the most important in this respect 
(Kanagy 2005). 
 
There is some debate over the relative importance of the receptor subtypes involved in 
mediating contractile responses to circulating catecholamines, which can cause 
vasoconstriction via α1- and via α2-adrenoceptors (Guimaraes and Moura 2001). One 
study in mice, using prazosin to block α1-adrenoceptor-mediated responses, estimated 
that between 55 and 68% of the vasopressor response to injected noradrenaline was 
mediated through α1-adrenoceptors (Duka et al. 2000). However, this study may have 
been flawed, because prazosin is also known to act as an antagonist to some extent at 
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α2B- and α2C-adrenoceptors (Kanagy 2005). There is some evidence that several 
pathophysiological features of cardiac arrest can increase the importance of α2-
adrenoceptor-mediated arteriolar vasoconstriction.  
 
In healthy subjects, the vasoconstrictor response to α2-adrenoceptor activation on 
smooth muscle is opposed by activation of endothelial α2-adrenoceptors which 
initiates the release of nitric oxide and other endothelium-derived vasodilator agents. 
Indeed, in rat aorta, treatment with a nitric oxide synthase inhibitor is required to 
unmask the vasoconstrictor response to α2-adrenoceptor stimulation (Kanagy 2005). 
This led to the suggestion that in intact arteries, the vasodilator (endothelial) effects of 
α2-adrenoceptor activation might outweigh the vasoconstrictor (smooth muscle) 
effects. There is a paucity of information regarding the relative vasodilator and 
vasoconstrictor responses to α2-adrenoceptor agonists in the arterioles, where 
vasopressors are intended to act during resuscitation. However, cardiovascular disease 
is likely to disrupt the balance of vasodilatation and vasoconstriction. Damage to the 
vascular endothelium is an important component of the pathophysiology of 
cardiovascular disease. Ischaemia also causes severe damage to the endothelium 
(Sapienza et al. 1996). Endothelial damage results in reduced endothelial vasodilator 
responses (Sapienza et al. 1996; Melo et al. 2004) and thus in patients presenting with 
cardiac arrest, the vasoconstrictor properties of α2-adrenoceptors may dominate over 
the endothelial vasodilator effects (Kanagy 2005).  
 
Vasoconstriction mediated by activation of α2-adrenoceptors can be readily 
demonstrated in animal models in vivo (Timmermans and Van Zwieten 1980; Van 
Meel et al. 1981). However, this vasoconstriction is difficult to replicate in isolated ex 
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vivo blood vessels. It has been suggested that this is due to the fact that α2-
adrenoceptors predominate in small resistance vessels, whereas larger arteries, often 
used for such studies are abundant in α1-adrenoceptors (McGrath 1982). This may 
have led to an underestimate of the importance of α2-adrenoceptors as 
vasoconstrictors. Studies of the locations of post-junctional α2-adrenoceptors in the 
porcine circulation have found them in arterioles, in cutaneous veins and arteries 
(Roberts et al. 1998) and in human omental arteries. In humans, there appears to be an 
inverse relationship between lumen diameter, and density of α2-adrenoceptors 
(Nielsen et al. 1991). Vasoconstrictor responses to α2-adrenoceptor stimulation have 
also been demonstrated in other small human arteries (Nielsen et al. 1991). 
Vasoconstriction in the human coronary circulation is mediated by both α1-
adrenocqeptors (in large vessels) and α2-adrenoceptors (in the microcirculation) 
(Gregorini et al. 1999; Gregorini et al. 2002) and reduces the blood supply to the 
myocardium. Thus, whilst α-adrenoceptor agonists cause peripheral vasoconstriction 
which is beneficial during cardiac arrest, the overall effect may be detrimental if 
myocardial blood-flow is reduced.  
 
It has been demonstrated, using human skeletal muscle arteries that ischaemia 
increases the vasoconstrictor response elicited by α2- (and α1-) adrenoceptors 
(Jarajapu et al. 2001). This may be another factor in allowing α2-adrenoceptor 
agonists to have an enhanced vasoconstrictor role during resuscitation. 
 
Vasodilatation of skeletal muscle vasculature is a classic ‘fight or flight’ response of 
adrenaline. The mechanism of the vasodilatiation is via the activation of β-
adrenoceptors. This vasodilator effect of adrenaline opposes the beneficial α-
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adrenoceptor-mediated vasoconstriction described above (Guimaraes and Moura 
2001).  
 
3.1.2 Action on cardiac adrenoceptors.  
In ventricular myocardium and the sino-atrial node, adrenaline acts predominantly on 
β1-adrenoceptors in the heart to mediate positive chronotropic and inotropic effects. 
This leads to an increase in oxygen demand in the myocardium. In the ischaemic 
heart, activation of β-adrenoceptors can therefore lead to a worsening of ischaemia. 
Carvedilol, an α1- and β-adrenoceptor antagonist, has been demonstrated to have 
beneficial effects during myocardial ischaemia (See section 4.2 below).  
 
The stimulation of α1-adrenoceptors may be undesirable in resuscitation because they 
are also found in the heart, where they mediate a positive inotropic effect, leading to 
an increased oxygen demand in the myocardium. This has been demonstrated both in 
the rat (Williamson and Broadley 1989; Broadley et al. 1999) and in human subjects 
(Landzberg et al. 1991). Although it should be noted, that when a non-selective 
adrenoceptor agonist such as adrenaline is given, the predominant effect on inotropy 
is likely to be through β-adrenoceptors. Despite the apparent contraindications to α1 
stimulation, some investigators have studied the possibility of using methoxamine, an 
α1-adrenoceptor agonist in the resuscitation setting. Two studies compared the use of 
this agent with adrenaline. In a canine model of resuscitation, methoxamine was 
found to be superior to adrenaline (Roberts et al. 1990), however in a clinical study 
adrenaline was superior (Olson et al. 1989).  
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Preliminary results from our laboratory demonstrate the adverse effects of adrenaline 
on myocardial stunning in rat isolated ventricular strips when adrenaline is given 
shortly prior to and during reperfusion (Figure 3). We are currently examining 
whether α-, β- or both adrenoceptor subtypes are involved in this deleterious effect.  
 
3.1.3 Vasopressors after ROSC.  
The resuscitated myocardium is likely to be stunned and thus pumping blood sub-
optimally. Positive inotropes such as dobutamine are clinically used to increase 
cardiac output (Mehta 2006). Selective vasopressors may be of use in directing 
residual cardiac output to the vital organs (Livesay et al. 1978). A recent analysis of 
clinical trial data has demonstrated a positive correlation between blood pressure after 
myocardial infarction and survival (Mayer and Schunkert 2007; Yap et al. 2007). This 
may seem surprising initially; however it highlights the importance of ensuring 
adequate perfusion of organs after myocardial damage. 
 
3.2 Miscellaneous properties of adrenaline relevant to 
resuscitation 
Adrenaline has a promiscuous pharmacological profile, being an agonist for at least 
nine different receptor subtypes. It has numerous effects which may detract from any 
beneficial effects in the resuscitation setting, these are discussed below. 
3.2.1 Coronary vasoconstriction 
The haemodynamics of adrenaline are complicated because it can cause 
vasoconstriction (α-adrenoceptors) and vasodilatiation (β-adrenoceptors). However 
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high-doses of adrenaline can result in coronary vasoconstriction (Karch 1989). This 
presents a major limitation to the use of adrenaline in resuscitation. 
 
3.2.2  Platelet aggregation 
It has been established experimentally that stimulation of 2-adrenoceptors induces 
platelet aggregation which will initiate blood clotting mechanisms (Cameron and 
Ardlie 1982). This occurs via the release of the pro-aggregatory thromboxane Α2 
(Shah et al. 2000). At a concentration of 14.3 μg/kg (the standard 1mg dose of 
adrenaline given to a 70 Kg patient), platelet aggregation is approximately 10% 
(Poullis 2000). However, at higher doses of adrenaline used in some studies (Wenzel 
et al. 1999) platelet aggregation might be in the region of 75% (Poullis 2000). Given 
that it is occlusion of a coronary artery by thrombus formation and subsequent 
myocardial ischaemia that results in the tissue damage of myocardial infarction, and, 
that thrombolytic drugs, such as streptokinase must be given to restore blood-flow, the 
rationale behind giving a prothrombotic agent in these patients seems questionable. If 
it is the 2-adrenoceptor which also has the beneficial effects in resuscitation, this fact 
could potentially limit the effectiveness of agents for resuscitation directed at this 
receptor (Table 2). However, the significance of this prothrombotic action may only 
be slight given that all myocardial infarction patients receive thrombolytic drugs as a 
matter of urgency (Mehta 2006). 
 
3.2.3 Oxidation of catecholamines 
Adrenaline can be oxidised in vivo by ceruloplasmin, a plasma α-globulin, by 
polymorphonucleocytes and by cytochrome oxidase (Behonick et al. 2001). Oxidation 
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products of adrenaline, of which adrenochrome is the main example (Green and 
Richter 1937) have been demonstrated to inhibit catechol-o-methyl transferase, an 
enzyme responsible for the inactivation of catecholamines (Abbs et al. 1967). This 
has the potential to further increase the concentrations of active catecholamines. 
 
The oxidation products of catecholamines have been known for some time to cause 
damage to myocardial tissue (Yates and Dhalla 1975; Dhalla et al. 1978) although it 
is not known if they are more or less harmful than adrenaline itself (Bindoli et al. 
1992; Behonick et al. 2001). It has been demonstrated that oxidation of 
catecholamines is partially responsible for the increased levels of free radicals 
observed during ischaemia. High levels of oxygen radicals are partly responsible for 
post-ischaemic contractile dysfunction because they cause peroxidation of membrane 
phospholipids, disrupting the structure of the membrane and increasing its 
permeability. This leads to cell death by necrotic mechanisms (Lazzarino et al. 1994; 
Moens et al. 2005). This suggests that non-catecholamine adrenoceptor agonists may 
prove more useful, although since endogenous catecholamine levels are greatly raised 
during ischaemic insult to the heart, the significance of this is hard to judge. 
 
3.2.4 Adrenoceptor desensitisation 
Adrenoceptors undergo desensitisation when exposed to high agonist concentrations. 
Adrenoceptors of the α1 subtype are particularly prone to desensitisation during 
cardiac arrest (Sun et al. 2001), and, together with the potentially deleterious effects 
of α-adrenoceptor activation during resuscitation, this has been used as an argument 
for the use of selective α2-adrenoceptor agonists for resuscitation (Sun et al. 2001). 
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3.2.5 Interactions with drugs concomitantly taken by patients. 
 
Many patients who present with acute myocardial infarction will have been prescribed 
drugs for existing cardiovascular conditions. These may include α-adrenoceptor 
antagonists such as prazosin and doxazosin and β-adrenoceptor antagonists and drugs 
which act as antagonists at both α- and β-adrenoceptors. Drugs acting on α-
adrenoceptors are used for a number of other conditions ranging from depression to 
benign prostatic hyperplasia (Hieble 2000). This potentially complicates the effects of 
giving adrenaline for resuscitation, in an unpredictable manner. 
3.2.6 Consequences of exposure to adrenaline at reperfusion 
Whilst the vasopressor actions of adrenaline may be of use in restoring circulation, the 
detrimental effects of clinically administered and endogenously released adrenaline 
may extend into reperfusion. The arrhythmogenic effects of α1-adrenoceptor 
activation have been described above. It has also been demonstrated that β-
adrenoceptors have functional importance during the period of reperfusion. β1- and β2 
-adrenoceptors may have differential effects on the stunned heart. It is reasonably 
clear that β1-adrenoceptor stimulation is detrimental, as evidenced by the fact that the 
β1 selective antagonists, metoprolol (Feuerstein et al. 1998) and bisoprolol (Gao et al. 
2000) reduced infarct size in a rabbit model of the ischaemic heart when antagonists 
were given five minutes prior to reperfusion. However, isoprenaline, a non-selective 
β1- β2-adrenoceptor agonist did not alter infarct size although it did provide inotropic 
support (LaBruno et al. 1998). This has led to the suggestion that non selective β-
adrenoceptor agonists exert beneficial effects due to β2-adrenoceptor activation, but 
this is negated by harmful β1 mediated effects (Broadley and Penson 2004) . An 
- 25 - 
   
overall detrimental effect of adrenaline on contractile recovery was shown in isolated 
rat ventricles when administered for five minutes at the end of a period of simulated 
ischaemia, and for the first fifteen minutes of reperfusion (Figure 3). Thus, further 
work is required to examine the effects of β2-adrenoceptor activation at reperfusion.  
3.2.7 Hypokalaemia induced by β-adrenoceptor activation 
Activation of β-adrenoceptors has been implicated in mediating the hypokalaemia 
which is seen upon administration of adrenaline in humans. Hypokalaemia can result 
in arrhythmias (Beers and Berkow 1999b), hence is undesirable in the treatment of 
cardiac arrest (Roffey et al. 2003). Adrenaline infusion has been shown to initiate 
electrocardiographic changes in man via a β2-adrenoceptor-induced hypokalaemia. It 
is not clear whether the timecourse of these effects would be relevant during cardiac 
arrest and resuscitation. However, in another study, low concentrations of adrenaline 
(up to 0.06 μg/kg/min) were infused into healthy men. The infusion resulted in 
hypokalaemia and disturbed repolarisation. However, when the plasma potassium was 
held constant via a potassium infusion, the electrophysiological disturbances 
remained. The authors attributed this result to a direct effect on the myocardium 
causing a lengthening of the QTc interval (Lee et al. 2003). It has also been shown in 
a cell-based model that adrenaline shortens the refractory period of the cardiac action 
potential, thus promoting fibrillations (Tovar and Jones 1997).  
3.2.8 Pulmonary ventilation/perfusion mismatching 
It has been demonstrated in an experimental study using dogs, that adrenaline has 
detrimental properties on pulmonary gas exchange during resuscitation. When regions 
of the lung become hypoxic (such as after respiratory arrest), hypoxic 
vasoconstriction in such areas directs blood-flow to better ventilated regions of the 
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lung. This vasoconstriction may be reversed by the activation of β-adrenoceptors by 
adrenaline, thus preventing the beneficial effects of this autoregulatory mechanism by 
diverting blood-flow away from better ventilated areas (Tang et al. 1991).  
3.2.9 Distribution of adrenaline. 
 
If the widely held theory that adrenaline exerts its beneficial effects through 
vasoconstriction in peripheral arterioles is correct (see section 1.4 above), the 
intravenous route of administration of adrenaline presents drug distribution problems. 
The poor cardiac output generated by chest compressions is not conducive to the rapid 
distribution of drugs. Additionally, before adrenaline can reach its site of action, it 
must pass through the heart and lungs, therefore it is likely to be present at higher 
concentrations in these organs, where a detrimental effect of adrenaline is predicted, 
rather than at its intended site of action in peripheral arterioles. Pharmacokinetic 
considerations in cardiac arrest have been extensively reviewed elsewhere (Pentel and 
Benowitz 1984). 
 
3.2.10 Effects of adrenaline on mast cells 
There is some evidence to demonstrate that the mast cell degranulation that occurs 
during ischaemia and reperfusion is mediated by activation of α1-adrenoceptors on the 
mast cells. The subsequent release of cytotoxic degranulation products such as mast 
cell peroxidase, leads to myocardial dysfunction (Parikh and Singh 1999). 
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4 Possible alternatives to the use of adrenaline 
The poor clinical outcome with adrenaline (Holmberg et al. 2002) has led to research 
being directed at developing alternative vasopressors for use in resuscitation. As 
described above, it has been suggested that stimulation of the α2-adrenoceptor and 
resultant vasoconstriction produces a beneficial effect during resuscitation, whilst 
responses mediated by other adrenoceptors are theoretically detrimental. This has 
provoked the suggestion that better results might be achieved by the use of more 
selective adrenoceptor agonists, of by directing the response to adrenaline selectively 
towards desirable receptor subtypes by the use of antagonists. Attempts have also 
been made to use non-adrenergic vasopressors in experimental and clinical models of 
cardiac arrest. These strategies are discussed below. 
 
4.1 Selective α-adrenoceptor agonists  
The promiscuous pharmacological profile of adrenaline has led to the suggestion that 
subtype-specific adrenoceptor agonists might prove more beneficial. The possibility 
of using selective α2-adrenoceptor agonists as vasopressor agents in resuscitation has 
been examined experimentally. The argument given is that activation of β-
adrenoceptors is detrimental in resuscitation, because they increase the energy 
requirements of the heart, as do α1-adrenoceptors to a lesser extent. The latter also 
become rapidly desensitised during ischaemia (Sun et al. 2001). Clonidine is 
unsuitable as it causes a paradoxical fall in blood pressure. This is due to activation of 
α2-adrenoceptors in the central nervous system causing a fall in blood pressure 
(Kanagy 2005).  
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The supposedly selective α2-adrenoceptor selective agonist, α-methylnoradrenaline 
has been suggested for use in resuscitation and it has proved promising in animal 
models of ischaemia reperfusion for the reasons outlined above. However, one small 
but well designed study in humans has cast doubt upon the usefulness of this drug 
because it showed no vasoconstrictor activity until β-adrenoceptors were blocked, 
suggesting that this agent acts additionally on β-adrenoceptors, opposing its beneficial 
vasoconstrictor response (Schafers et al. 1999).  
 
As described above, post-junctional smooth muscle α2-adrenoceptors cause 
vasoconstriction, whereas pre-junctional α2-adrenoceptors prevent neuronal 
noradrenaline release and the resulting vasoconstriction (Table 1). Endothelial α2-
adrenoceptors cause vasodilatation by a nitric-oxide mediated mechanism. The effect 
of adrenaline on endothelial α2-adrenoceptors is likely to counteract the beneficial 
vasopressor effects of α2-adrenoceptor agonists. It is by no means clear whether 
activation of pre-junctional α2-adrenoceptors would be beneficial or detrimental 
during resuscitation. High levels of endogenous catecholamines during resuscitation 
have been linked with a poor chance of survival, and thus it has been argued that 
stimulation of pre-junctional α2-adrenoceptors to inhibit neuronal noradrenaline 
release would be expected to be advantageous (Sun et al. 2001). One possible 
approach to developing a new vasopressor for resuscitation would be to use a 
selective agonist with exclusively vasoconstrictor properties. Such an approach would 
prove challenging as the same subtype of adrenoceptor (α2A) appears to mediate both 
vasoconstriction (via receptors located on smooth-muscle) and vasodilatation (via 
endothelial receptors).  
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One major limitation of this approach has been highlighted by a study in dogs, which 
demonstrated that when the coronary circulation is under-perfused, activation of α2 
adrenoceptors leads to a profound vasoconstriction in coronary arterioles. If this effect 
were to occur in humans, it would seem to preclude the use of α2-adrenoceptoer 
agonists for resuscitation (Chilian 1991). 
 
An intriguing possibility, that does not seem to have been considered elsewhere is that 
the α2 adrenoceptors agonist effects of adrenaline are beneficial, but through venous 
rather than arteriolar constriction. It is possible that constriction of capacitance vessels 
would increase venous return and improve right atrial filling. Although there is no 
direct evidence to support this theory, it is interesting to note a beneficial effect of 
devices which compress veins i.e. cause mechanical venoconstriction. ‘Military 
antishock trousers’ have been shown to improve coronary and cerebral blood-flow 
during CPR (Lilja et al. 1981; Warren et al. 1983). The theory behind these devices is 
that they prevent venous pooling in the lower extremities and essentially perform an 
‘autotransfusion of blood’. The same theory lies behind the G-suits used by fighter 
pilots to prevent blacking out during high-speed manoeuvres. Interestingly the idea 
can be traced back to George Crile, one of the first investigators to use adrenaline in 
CPR (Sternbach 1984).  
 
4.2 Directing endogenous and administered adrenaline 
towards α2- adrenoceptors with antagonists.  
Directing the effects of adrenaline towards specific receptor subtypes by the 
concurrent administration of subtype-specific adrenoceptor antagonists has been 
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suggested. The advantage of this approach is that it may reduce the deleterious effects 
of the massive endogenous release of catecholamines which takes place during 
cardiac ischaemia (Niemann and Garner 2005).    
 
Based on the theory that α2-adrenergic receptors would be beneficial at resuscitation 
(Sun et al. 2001), one study treated rats with carvedilol, an antagonist at 1- , 1-  and 
2-  adrenoceptors, prior to adrenaline treatment. It was demonstrated that after 
induced ventricular fibrillation and adrenaline administration during resuscitation, 
carvedilol pre-treated animals had significantly better myocardial and neurological 
function than controls. Importantly, survival was also significantly increased from 
4522 hours to 711 hour (Huang et al. 2006). 
 
Carvedilol improves efficiency of energy production hence prevents build up of 
oxygen free radicals which frequently occur upon reperfusion. This effect has been 
demonstrated to be independent of the antioxidant properties of carvedilol and is thus 
probably receptor mediated (Monteiro et al. 2003). This could be confirmed by 
comparing the (+) and (-) stereoisomeric forms of carvedilol, both isomers 
presumably having equal non-receptor properties such as antioxidant activity. 
However, no clinical studies using adrenaline after carvedilol treatment appear to 
have been performed. 
 
4.3 Non adrenergic vasopressor agents. 
Vasopressin, alternatively known as anti-diuretic hormone, is released from the 
posterior pituitary in response to dehydration and has a two-fold effect on blood 
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pressure. It increases the permeability of the kidney tubule, increasing re-absorption 
of water and hence expanding blood volume. It also has a vasoconstrictor action on 
peripheral arterioles (Ganong 2001). Experimental results show a benefit over 
adrenaline (Johansson et al. 2004). Clinical results are described below (section 6.4). 
Endothelin-1 has also been investigated in a swine model of resuscitation. It was 
shown to increase coronary perfusion pressure but did not affect the likelihood of 
ROSC.  (DeBehnke et al. 1996; DeBehnke 2000; DeBehnke and Benson 2000). As 
yet, no clinical studies using this agent appear to have been carried out. 
 
However, a major contra-indication exists to the use of either of these agents in the 
resuscitation setting. They are both strong coronary vasoconstrictors (Martinez et al. 
2003). This effect may outweigh any increase in coronary flow achieved by peripheral 
vasoconstriction. 
4.4 Ideal properties of resuscitation vasopressor 
Many vasopressor drugs are available, although relatively few have been extensively 
tested as candidates for use in CPR. It is possible that an as yet unexamined 
vasopressor may be more beneficial than any current agent. The ideal compound 
would improve the chance of ROSC and would improve long-term survival. When 
deciding which drugs to put forward for further testing in this field, it is suggested that 
a vasopressor with the following ‘ideal’ properties is sought. The drug or combination 
of drugs should: 
 
 Constrict peripheral arterioles. 
 Not constrict coronary or cerebral vessels (coronary vasodilator would be 
beneficial). 
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 Not increase myocardial oxygen consumption. 
 Not increase platelet aggregation or blood coagulation. 
 Have a relatively long plasma half-life to allow infrequent dosing during 
resuscitation. 
 Not yield any metabolites that oppose the beneficial effects or have toxic 
properties. 
 Protect against the harmful effects of raised levels of endogenous 
catecholamines but spare any beneficial properties. 
 Not have any adverse effects upon reperfusion injury. 
 
4.5 General effects of vasopressors which may limit 
usefulness during resuscitation 
 
Ischaemic damage and reperfusion injury in the heart have been discussed above, 
however the mechanisms involved are applicable in various tissue types throughout 
the body. Because of the lack of blood flow, ischaemia of an organ or tissue causes 
the accumulation of waste products of metabolism locally. Upon reperfusion, these 
can be released into the general circulation and have deleterious consequences on 
distant organs. For example, tumour necrosis factor-α, a pro-inflammatory cytokine 
released into the circulation from all ischaemic tissues can compromise cardiac 
function and increase reperfusion injury (Blancke et al. 2005). This has been 
extensively reviewed elsewhere (Tisi and Shearman 1999). Ischaemia and reperfusion 
in a limb can cause a systemic reaction in which the function of multiple organs is 
disrupted (Yassin et al. 2002). Theoretically therefore, causing vasoconstriction in 
- 33 - 
   
peripheral blood vessels could worsen the ischaemic damage and consequent events at 
reperfusion. However, given that peripheral tissues are probably minimally perfused 
during CPR, the relevance of vasoconstriction may be minimal.  
 
Vasopressors, by their very nature constrict blood vessels. This can prevent drug 
distribution in the circulatory system. Indeed, adrenaline is often given in combination 
with local anaesthetics to reduce local blood flow thus decreasing the amount of 
systemic absorption and prolonging local anaesthetic effects (Mehta 2006). Thus, 
when intended for systemic effects as in resuscitation, it may be difficult for 
vasopressors to reach their site of action, unless they have a high selectivity for 
particular peripheral vascular beds. 
 
Case reports suggest that adrenaline administration can lead to intracranial 
haemorrhage (Choudhary et al. 1999; Cartwright and Reynolds 2005; Kwon et al. 
2007). This is likely to result from its vasopressor effect, and may be of concern 
immediately after the ROSC, when circulating levels of the vasopressor drug may still 
be high.  
 
5 Experimental models 
A variety of experimental models have been used to study the effects of drugs on 
ischaemic damage and reperfusion injury. Laboratory methods have proved useful in 
preclinical investigation of drugs used during resuscitation and are extensively 
employed, although there is often a disparity between experimental findings and 
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clinical results. To date, no model has been validated, such that it can reliably predict 
the results of an intervention in the clinical setting. 
5.1  In vivo experiments 
In vivo models provide the most realistic tool for the experimental study of 
resuscitation. Various species have been used including rats (Klouche et al. 2003; 
Kolarova et al. 2005), dogs (Roberts et al. 1990) and pigs (Pellis et al. 2003; Niemann 
and Garner 2005). There is a wide distribution in the extent of coronary collateral 
circulation between species, meaning that selection of an appropriate species is 
essential. The collateral flow can be determined after the occlusion of a major 
coronary artery. It is defined as the amount of flow received by an ischaemic area of 
myocardium, as a percentage of that received by a non ischaemic region. In guinea 
pigs the collateral flow is close to 100%, whereas in dogs, it is less than 20%, and in 
rats less than 10% (Hearse 2000). In humans, the extent of coronary collateral 
circulation is very variable, however it is positively correlated with the degree of 
coronary artery stenosis (Fujita and Tambara 2004). Therefore, patients presenting 
with cardiac arrest following quite a long period of ischaemic heart disease, are likely 
to have well developed collateral circulation. The most common method of induction 
of cardiac arrest in experimental models is the application of a 60 Hz alternating 
current to the ventricular tissue or the thorax. This is a poor model for the majority of 
cardiac arrests, which usually result from coronary thrombosis leading to infarct 
formation (Camm 2002). This fact may go some way to explaining the discrepancy 
between the results obtained in vivo and in vitro. More clinically relevant results may 
be obtained when ischaemic cardiac arrest is initiated by coronary ligation. Whilst this 
technique has been used in the study of ischemia and reperfusion injury, it does not 
seem to have been applied to the study of resuscitation. Of interest, one group has 
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recently developed a model of cardiac arrest following chronic myocardial ischaemia 
following experimental coronary constriction. However, even in this model, cardiac 
arrest was initiated by electric shock (Fang et al. 2006). Developments such as this, 
which bring the experimental setting closer to reality may improve the reliability of 
experimental results in predicting outcomes in the clinic. 
 
Despite their limitations, in vivo models have manifold advantages over in vitro 
experiments. When in vivo models are used, pharmacological agents are subject to 
similar metabolic processes that exist in the clinic. These models also replicate the 
conditions of arrested blood-flow during cardiac arrest and the subsequent difficulties 
in achieving drug distribution. Agents can be introduced into the circulatory system at 
the time of resuscitation, thus replicating the clinical situation. In vivo models provide 
a platform for the study of the survival of experimental animals over a relatively long 
term.  
5.2 In vitro isolated organs and cell culture methods 
In vitro laboratory methods usually rely on simulating ischaemia in whole perfused 
isolated hearts, isolated atria, ventricular strips, papillary muscles or even cultured 
cardiomyocytes before reperfusing the tissues and measuring the recovery in terms of 
the contractile function of the myocardium or by measuring the levels of cardiac 
damage indirectly. Drugs or interventions can be introduced at various points during 
ischaemia and reperfusion, and their effects on ischaemic damage and reperfusion 
injury examined. 
 
Such reductionist approaches can be extremely useful in separating out the 
mechanism of action of a drug with complex pharmacological effects, such as 
- 36 - 
   
adrenaline. However the limitations of such techniques must be borne in mind. Firstly 
models using isolated hearts or cardiac tissues do not include the peripheral 
vasculature where adrenaline and other vasopressors are supposes to exert their 
beneficial effects. Such models will only demonstrate the myocardial and coronary 
vascular effects of these interventions, which may not always be beneficial (see 
Figure 3). Secondly, the tissues inevitably become ischaemic whilst they are being 
removed from the animal and prior to set up. This ischaemia may be sufficient to 
activate ischaemic preconditioning, a cardioprotective phenomenon whereby short 
periods of ischaemia initiate pro-survival signalling within cells and protect against 
the damage caused by subsequent ischaemic episodes (Murry et al. 1986; Awan et al. 
1999; Yellon and Downey 2003). Thirdly, isolated cardiac preparations are rarely 
viable for long enough to determine whether any myocardial dysfunction is due to 
permanent cell death or reversible stunning. 
 
5.3 Cardioactive properties of agents used in experimental 
models 
 
Care needs to be taken in the interpretation of many in vivo and ex vivo experiments in 
the field of ischaemia and reperfusion injury. In order to carry out surgical procedures 
in animals as part of in vivo studies anaesthetic must be given. Similarly, when setting 
up the isolated perfused heart model, it is common to kill the animal using an 
overdose of pentobarbital followed by exsanguination; heparin is also commonly 
given to prevent thrombus formation in the heart. However, both anaesthetics (Weber 
and Schlack 2005) and heparin (Kilgore et al. 1999) have been demonstrated to exert 
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cardioprotective effects during ischaemia thus reducing the potential window of 
opportunity upon which cardioprotective interventions can act. 
5.4 Why are models a poor representation of the clinical 
situation? 
No experimental model of resuscitation has so far provided realistic predictions of 
clinical performance of an intervention. As a general trend, treatments which seem 
promising in experimental settings often prove disappointing in the clinic. A number 
of factors may be individually or collectively responsible for these discrepancies.  
 
It is reasonable to expect in-vivo models, especially in larger animals such as pigs and 
dogs to give a good indication of how an intervention will perform in the clinic. This 
has not been the case. For instance, in their ground-breaking work, Pearson and 
Redding proudly announced  
 
“with no drug, or with sodium bicarbonate (2mEq. per kg.) we could restore 
circulation in only 10-20% of cases. With adrenaline we could restore circulation in 
95-100%”. (Pearson and Redding 1964a) 
 
Sadly, the rate of survival to discharge from hospital in patients suffering cardiac 
arrest out of hospital is less than 3% (Gueugniaud et al. 1998) and may reach 16 % 
when cardiac arrest occurs in hospital (Cooper et al. 2006) but is, in any case, rather 
less than Pearson and Redding’s confident predictions.  
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Another problem is that most investigators utilise young healthy animals in their 
research, rather than animals which accurately reflect the multiple pathologies which 
are present in elderly patients who present with cardiac arrest secondary to myocardial 
infarction. Differences in blood pressure and the extent of coronary collateral 
circulation between young and old animals may have a major effect on the 
experimental results obtained.  
 
Endpoints in experimental models have included ROSC (Hilwig et al. 2000), 24 hr 
survival (Kern et al. 1988; Hilwig et al. 2000), coronary perfusion pressure (Kolarova 
et al. 2005) and ventricular ectopic activity (arrhythmias) (Kolarova et al. 2005). 
Clinical end points have included ROSC, survival to hospital admission (where 
treatment was given outside hospital), survival to hospital discharge, neurological 
outcomes and survival to various other temporal endpoints. The variety of end points 
chosen and the manifold number of different protocols employed make the 
comparison of results from different studies very difficult indeed.  
 
It could be argued that when investigating CPR where chest compressions are given 
in addition to pharmacological agents, the use of small animals may not provide a 
very realistic model. Animals of approximately the same size as humans, such as pigs 
may give better predictions of clinical outcomes. 
 
6 Clinical evidence 
Numerous clinical trials of adrenaline have been carried out in the resuscitation 
setting. Trials have been designed to answer one or more of the following questions: 
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Is adrenaline more effective than placebo control in CPR? Does high dose adrenaline 
produce better results than the standard dose? Are subtype-specific adrenoceptor 
agonists superior to adrenaline? Is the response to adrenaline improved when specific 
antagonists are given concurrently? Do non-adrenergic vasopressors produce better 
results than adrenaline? The designs and outcomes of these questions will be 
discussed below. Additionally a number of studies have examined the role of 
adrenaline in paediatric resuscitation, although this subject is outside the scope of this 
review and will not be discussed. 
 
Although a large number of studies have been carried out, interpretation of the results 
is difficult because of the variety of endpoints used in studies. These have ranged 
from the most basis studies which used the ROSC as the endpoint (taking no account 
of the fate of the patient thereafter) to complex studies which have monitored survival 
over a number of months and have included monitoring of patients neurological 
function. Most studies have been conducted on a small scale, presumably due to 
limited funding and facilities; these studies have had limited power to detect 
differences between treatment groups. Many studies have included inherent scientific 
weaknesses, such as not being blinded to the physician or not including a placebo 
control. Several studies that were blinded included a direction that adrenaline be 
administered to the patient if the trial drug failed. These aspects of trials have been 
included on the basis of sound ethical reasoning, however they make it difficult to 
draw definitive conclusions. 
 
Numerous studies have examined the effects of high and standard doses of adrenaline. 
The current guidelines for the administration of adrenaline allow for the repeated 
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administration of the drug (Figure 1), and this too was the case for experimental 
agents. Where doses of drug are cited in the text below, they refer to the dose given in 
each individual bolus rather than the total dose administered, except where stated 
otherwise. 
 
6.1 Comparison of standard-dose adrenaline and placebo 
For ethical reasons, no blinded randomised trials of adrenaline in the resuscitation 
setting have included a placebo control group (American Heart Association 2005). 
Several investigators have compared the outcome of groups of patients treated with 
adrenaline, with those not treated with adrenaline. This comparison is, however, 
inherently biased, because patients treated with adrenaline are more likely to be 
complicated cases, who do not respond to initial defibrillation. This makes 
interpretation of the data very difficult.  
 
A retrospective study was carried out in Sweden examining the role of adrenaline in 
treating out-of-hospital cardiac arrest over a twelve year period. The records of 1360 
patients were examined. Adrenaline was given to 35% of patients and did not result in 
any change in the survival of patients to hospital discharge compared with untreated 
patients. However, as the authors conceded the trial was not randomised, and a major 
confounding factor was that the patients treated with adrenaline were generally those 
who presented with more complicated clinical conditions (Herlitz et al. 1995) 
 
A later, larger (10966 patients) prospective evaluation of adrenaline in CPR was 
carried out by the same group of researchers. A more clinically useful endpoint, 
survival to 1 month after cardiac arrest, was employed. Using multivariate analysis, 
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the use of adrenaline was found to be independently correlated with poor survival, 
especially in patients presenting with non-shockable cardiac rhythms (Holmberg et al. 
2002). This study was also limited by the lack of randomisation, and differences in 
baseline variables between patient groups. 
 
An Australian group, also claim to have compared both high- and standard-dose 
adrenaline with placebo in cardiac arrest. They found no difference in survival to 
hospital discharge between the groups and the overall hospital discharge rate was 
0.9%. This trial in 339 patients probably represents the best attempt at conducting a 
placebo-controlled clinical trial of adrenaline in CPR to date. However, the results 
must be taken with caution, as the trial was neither randomised nor blinded, and the 
results demonstrated a bias of physicians for treating certain patient groups with 
standard-dose adrenaline. (Woodhouse et al. 1995). 
 
One study recruited 199 patients in ventricular fibrillation who had failed to respond 
to one defibrillation attempt. The patients were randomised to receive endotracheal 
adrenaline or lidocaine to compare the effectiveness of these two drugs in 
resuscitation. These patients were compared with a group of 630 historical controls, 
treated with only sodium bicarbonate. The results of this study are hard to determine, 
as the number of patients available for analysis was reduced by poor compliance with 
study protocol. Survival to hospital discharge was significantly smaller (16%) in 
patients treated with adrenaline, than in patients treated with sodium bicarbonate or no 
drug (38%) (Olson et al. 1989) 
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In conclusion, no trial has identified a benefit of adrenaline over placebo in CPR, 
although is should be borne in mind, that the quality of the investigations carried out 
to date is rather poor.  
 
6.2 High-dose adrenaline 
 
The standard dose of 1mg adrenaline was taken directly from Redding and Pearson’s 
early studies in dogs. More recently, concern was raised that due to the difference in 
mass between the dogs used in the study and an adult human, the dose of adrenaline 
used in the study was too small. Additionally, it was shown that at doses above 1mg, a 
dose-dependent vasopressor relationship existed to adrenaline in human beings during 
CPR (Gonzalez et al. 1989). In other words, at 1mg the dose was submaximal. In 
dogs, it was shown that the peripheral vasoconstrictor effects of adrenaline were 
responsible for the beneficial effects (Michael et al. 1984). Thus numerous trials have 
been carried out to compare the effects of high-dose adrenaline (up to 10 mg) with 
standard protocol. Some of these trials are of a high standard, being both randomised 
and blinded. 
 
In the 1990s Barton and Callaham published a series of papers investigating treatment 
of cardiac arrest with standard- and high-dose adrenaline. They initially carried out a 
small trial on 49 patients. Apart from its small size, the trial suffered considerable 
weaknesses, in that it was not blinded, not randomised and the data was gathered 
retrospectively. However a trend towards a higher rate of ROSC was seen in high-
dose treated patients (Barton and Callaham 1991). 
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These investigators set out to determine whether high-dose adrenaline was associated 
with a higher incidence of complications than normal dose. 68 patients with non-
traumatic cardiac arrest were recruited into the study. The study was not randomised 
and physicians treated as they saw fit. Patients were retrospectively allocated to the 
high dose or low dose group, depending on whether they had received greater or less 
than 2.8 μg kg-1 min-1. Additionally those patients who had received a bolus of 50 μg 
kg-1were included in the high dose group (Callaham et al. 1991). The study was 
therefore somewhat flawed as it was not comparing two distinct doses, rather it was 
looking at a sliding scale with an arbitrary dividing line. The only significant 
difference between the two trials in terms of complications was a greater depression 
of serum calcium in the high dose adrenaline group. No significant difference was 
seen in survival to hospital discharge, although 30 % of patients in the standard dose 
group survived, compared with 18 % of high-dose treated patients. Although no 
conclusions can be drawn in the absence of statistical significance, the trial was 
probably underpowered to detect a survival difference, and the results of the low-dose 
treated group seem more promising. 
 
The same group of investigators went on to carry out a randomised clinical trial of 
high-dose adrenaline and standard dose adrenaline in pre-hospital cardiac arrest. The 
study enrolled 816 patients. Noradrenaline was also examined as a vasopressor in this 
trial, and the results are discussed elsewhere. In addition to ROSC, additional 
outcome measures were included. These were survival to hospital admission, survival 
to hospital discharge and their Cerebral Performance Category score (a measure of 
mental function and capacity) whilst in hospital. High dose adrenaline increased the 
probability of achieving ROSC. In the high dose group, circulation was restored in 
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13% of patients, compared with 8% for standard dose adrenaline. However no 
statistically significant increase to hospital discharge was noted, although this trial 
was probably underpowered to detect any such change (Callaham et al. 1992). 
 
At around the same time another group carried out a randomised trial of standard and 
high-dose adrenaline, specifically in asystole and electromechanical dissociation. The 
trial included 68 adult patients and was blinded. Survival to hospital discharge was 
taken to be the endpoint.  There was a trend towards a higher rate of discharge in the 
high-dose adrenaline group, although this did not reach statistical significance. Blood 
pressure was, however higher at 1 and 5 minutes post-resuscitation, the rate of initial 
restoration of circulation was better in high dose treated groups (57 % v. 15 %) and 
there was no difference in the incidence of adverse effects between groups (Lindner et 
al. 1991a). 
 
Paradis’ group have long been interested in resuscitation. In one early study they 
examined the effects of coronary perfusion pressure on the ROSC. The trial was 
relatively small, recruiting 100 patients. In addition to the main focus of the study, the 
investigators also analysed some data relating to patients in the study who had been 
treated with high-dose rather than standard dose adrenaline. No difference was seen in 
terms of achievement of ROSC and no patients in either group survived to hospital 
discharge. Results from the trial gave some indication that high coronary perfusion 
pressures were correlated with good rates of ROSC, confirming data seen elsewhere 
in animal models. It was tentatively suggested that a coronary perfusion pressure of 
15 mmHg might be a cut-off point below which ROSC was unlikely or impossible 
(Paradis et al. 1990).  The group therefore went on to carry out a small (32 patients) 
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clinical trial, designed to address specifically the question of how high- and low dose 
adrenaline affected coronary perfusion pressure during CPR. They discovered that 
high dose adrenaline was more effective than standard dose at raising the coronary 
perfusion pressure above their previously defined critical level and hence they 
tentatively concluded that high-dose adrenaline may be more effective at achieving 
ROSC than the standard dose.(Paradis et al. 1991) 
 
The ‘Multicenter High-Dose Epinephrine Study Group’ performed a large trial 
comparing standard and high dose adrenaline in cardiac arrest outside the hospital. 
1280 patients were randomised to receive either 0.02 mg/kg or 0.2 mg/kg 
intravenously. The study included patients presenting with any presenting rhythm and 
examined multiple endpoints including ROSC, survival to hospital admission, 
survival to hospital discharge and neurological outcome. No difference could be 
found between the two groups with respect to any of these outcomes. The authors 
attributed this failure to the delay in reaching the patient, and the extensive ischaemic 
damage already occurred (Brown et al. 1992). 
 
At one hospital, the resuscitation protocols were radically altered. Initially no 
adrenaline was used in resuscitation, however guidelines then changed and suggested 
physicians use high dose (10 mg adrenaline). A retrospective analysis was then 
carried out; investigating the success of resuscitation before and after the protocol was 
changed. Immediate survival was 43% in patients who did not receive adrenaline, but 
only 22% in high-dose treated patients. This difference was statistically significant 
(Marwick et al. 1988). The weakness of the study was that, as a retrospective analysis, 
it could not be randomised, however, the study focused on patients presenting with 
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ventricular fibrillation after failure to respond to initial defibrillation, and was thus 
more focussed than other studies. Of 210 patients, 77 received high dose adrenaline 
and the rest received no drug. Multiple logistic regression showed adrenaline to be an 
independent predictor of poor outcome but no significant difference was seen in 
survival to hospital discharge, although as the authors pointed out, the number of 
patients to survive to discharge was too small.  
 
One study attempted to determine whether high dose adrenaline could exert any 
beneficial effects after the failure of standard therapy (Sherman et al. 1997). Although 
small (140 patients), this study had the advantage of being blinded and randomised. 
No benefit of high-dose adrenaline was seen in terms of any of the outcome measures. 
It should be remembered, that the ischaemic damage to the heart, and other organs are 
likely to be very high after initial treatments have been tried and have failed. It would 
be surprising if any intervention could be of benefit at this stage. 
 
The ‘European Epinephrine Study Group’ conducted a large (3327 patients) multi-
centre randomised trial comparing the use of high dose (5mg) and standard dose (1 
mg) adrenaline in cardiac arrest outside the hospital (Gueugniaud et al. 1998). The 
investigators found a small increase in the likelihood of restoring circulation when 
high dose adrenaline was used ( 40.4% v. 36.4 %). Analysis of subgroups revealed 
that high-dose adrenaline improved the chances of restoring circulation in patients 
with asystole, but not when ventricular fibrillation was the presenting rhythm. No 
difference was seen between the groups in terms of survival to hospital discharge or in 
terms of neurological outcome. 
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One group carried out a randomised, blinded trial comparing standard (1mg) and high 
(10mg) doses of adrenaline in asystole. The investigators did not find any difference 
in survival between the groups in terms of survival, although the study was extremely 
small, recruiting only 40 patients, and was thus vastly underpowered to detect any 
such changes (Lipman et al. 1993). 
 
A retrospective study of 178 patients in ventricular fibrillation showed that high 
cumulative doses of adrenaline given during resuscitation were correlated with poor 
neurological outcome as assessed by the cerebral performance score (Behringer et al. 
1998).  
 
In conclusion, it seems that high dose adrenaline is more efficient at achieving a 
ROSC than the standard dose, but no trial has shown an increase in survival to 
hospital discharge, or any improvement in long-term neurological function in 
survivors. On this basis, the use of high dose adrenaline may be unwarranted; the 
benefit to the patient, of achieving ROSC but dieing soon after certainly seems 
negligible. One interpretation of this data is that the increased benefit from the 
additional vasopressor effect of high dose adrenaline, is counterbalanced by increased 
adverse effects 
 
6.3 Other Adrenergic agents 
 
Noradrenaline has been compared with adrenaline in one randomised clinical trial of 
out of hospital resuscitation. No significant difference was seen between standard 
dose adrenaline and noradrenaline (11mg). However there was a trend towards a 
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better initial achievement of ROSC but worse neurological recovery in patients 
treated with noradrenaline (Callaham et al. 1992). 
 
One randomised study including 102 patients set out to compare adrenaline with the 
α1-adrenoceptor selective agonist, methoxamine, in resuscitation from ventricular 
fibrillation (Olson et al. 1989). The study was carefully designed and equipressor 
doses of each drug were given. Methoxamine was less effective at achieving ROSC 
than was adrenaline. However this study was very interesting, since the dose of 
adrenaline given was 0.5 mg. This is half the clinically recommended dose. However, 
19.6 % of patients in the adrenaline group were discharged alive from hospital, a 
reasonably high figure by the standards of resuscitation trials . This result should be 
followed up with a larger comparison of standard and low dose adrenaline and ideally 
a placebo group, to discover firstly, whether or not adrenaline is beneficial in 
resuscitation, and if this is the case, to enable the optimal dose of adrenaline to be 
discovered. 
 
6.4 Non adrenergic vasopressors 
After initial successes in animal models and the observation that vasopressin can 
increase coronary perfusion pressure during human cardiopulmonary resuscitation 
(Morris et al. 1997), several studies of resuscitation using vasopressin in humans have 
been carried out, despite the fact that this drug is known to be a coronary 
vasoconstrictor (Martinez et al. 2003). 
 
In a small (8 patients)  early study, it was shown that vasopressin may be more 
effective than adrenaline at achieving ROSC from cardiac arrest (Lindner et al. 
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1996b). This group went on to echo their findings in a larger (40 patient) study 
(Lindner et al. 1997) which recruited patients in ventricular fibrillation, and showed a 
benefit of vasopressin over adrenaline in initially restoring circulation. 
 
Stiell carried out a randomised, triple blind, controlled trial, comparing adrenaline 
(1mg) or vasopressin (40U) in cardiac arrests which occurred in the hospital. 200 
patients were recruited into the study, which found no difference between the patient 
groups in terms of 1 hour survival or survival to hospital discharge. The authors 
concluded that vasopressin should not be recommended for CPR (Stiell et al. 2001) 
 
In the biggest comparison of vasopressin and adrenaline carried out so far, 1219 
patients who had suffered cardiac arrest outside the hospital were randomised to 
receive either adrenaline (1mg) or vasopressin (40U). One of the endpoints uses was 
survival to hospital admission. Whilst no overall difference was seen between the 
groups, the large number of patients recruited into the study enabled analysis of 
subgroups to be carried out. It was found that when the presenting rhythm was 
asystole, patients treated with vasopressin were more likely to survive to hospital 
discharge than adrenaline treated patients. (Wenzel et al. 2004) 
 
6.5 Vasopressor combinations 
One study, including 298 patients, found that administering adrenaline together with 
vasopressin resulted in a greater rate of success then when adrenaline was used alone. 
The authors suggested that the synergistic vasopressor effects of the two drugs 
allowed smaller then usual doses of each to be given, thus reducing adverse effects. In 
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fact, in this trial the same total dose of adrenaline (3.8 mg) was given to both groups 
of patients (Guyette et al. 2004).  
 
6.6 Conclusions from clinical trials 
There are no studies that show adrenaline to be better than placebo in terms of 
survival. Higher than standard adrenaline doses do not lead to better results, and may 
in fact lead to worse outcomes. The results of some studies suggest that vasopressin 
may be more effective than adrenaline; one study even suggests that it may improve 
survival to hospital discharge in patients with asystole (Wenzel et al. 2004). However 
the results of the clinical trials must be taken with caution, many published data were 
analysed retrospectively, and hence were not randomised. Several trials recruited a 
wide variety of patients (different presenting rhythms, different duration of cardiac 
arrest etc.) and simply did not include a sufficient number of patients to detect the 
differences they were attempting to measure. A major conclusion from clinical trials 
is that more clinical trials are needed. If relatively small trials (<1000 patients) are 
carried out, they should be focused to answer a very specific question such as “is 
standard dose adrenaline superior to placebo in improving the survival to hospital 
discharge in patients with ventricular fibrillation of less than 10 minutes duration?”. 
There therefore appears to be an urgent need for large multinational trials with the 
power to detect differences between the many different subtypes of patients. 
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7 Conclusions 
There is a mounting body of evidence to suggest that adrenaline is less than ideal as a 
vasopressor agent when used in CPR. In answer to the question posed by the title of 
this review, the pharmacological basis for current clinical practice, the use of 
adrenaline as a vasopressor in resuscitation, is extremely limited. It certainly does not 
stand up to the rigour of ‘evidence based medicine’. In the context of CPR, adrenaline 
raises blood pressure and increases coronary and cerebral perfusion by causing 
systemic vasoconstriction, an effect thought to be mediated by α2-adrenoceptors. 
However, it also stimulates α1, β1 and β2 adrenoceptors leading to potentially 
detrimental effects during ischaemia and upon the reperfusion of the myocardium and 
other tissues which occurs with the ROSC.  
 
Adrenaline was introduced as an agent for CPR at a time when our knowledge of 
pharmacology was extremely limited. Indeed it preceded by over fifty years, 
Ahlquist’s description of the  α and β effects of adrenaline (Ahlquist 1948). With our 
modern understanding of receptor subtypes, it is probable that more selective 
adrenoceptor agonists, or indeed non adrenergic vasopressor agents could be used to 
much greater effect. However, in clinical trials, newer agents have not been proven 
conclusively to be any more effective than adrenaline and the recommendation of its 
use has remained largely unchanged since 1906.  
 
Some clinical evidence seems to suggest that different presenting arrhythmias respond 
better to different treatments. For example, vasopressin seems to be more effective 
than adrenaline in treating asystole. (Wenzel et al. 2004). When more evidence 
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regarding such patterns emerges, it may be possible to recommend different 
vasopressor agents for different arrhythmic states rather than using the current ‘one-
size-fits-all’ approach. Further to this, the time for which the heart has been ischaemic 
prior to resuscitation may have a bearing on the optimum treatment. Pearson & 
Redding suggested in the 1960s that there are two phases to cardiovascular 
resuscitation (before and after ROSC) (Pearson and Redding 1964b), however, the 
more sophisticated three-phase model of cardiac arrest recently proposed by Weisfeldt 
and Becker (2002), may prove more useful in directing therapies to achieve optimum 
results.  
 
Care must be taken when interpreting the outcomes of clinical trials, particularly with 
respect to the endpoints used. Several studies have claimed benefit of a particular 
agent or protocol on the basis that it improved the likelihood of restoration of 
circulation, without an improvement in the rate of hospital discharge. It has been 
argued that this endpoint is valid, because many factors apart from the resuscitation 
protocol influence whether or not the patient is discharged alive (Callaham et al. 
1992). However, one has to question whether initial resuscitation, followed soon after 
by death is of any benefit to the patient. 
 
Vasopressor agents should be screened for compliance to the ‘ideal’ properties for 
vasopressor resuscitation agents listed above. Careful attention should be paid to the 
experimental models used in evaluating novel drugs, to enable useful medicines to be 
taken forward into the clinic. However, it should be borne in mind that the poor 
results of all agents used in clinical trials may indicate that arteriolar vasopressors are 
not a suitable treatment for cardiac arrest. A balance needs to be struck between 
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maintaining sufficient coronary flow to allow ROSC, and preventing ischaemic 
damage to tissues caused by vasopressors (and subsequent systemic effects at 
reperfusion). A further problem with vasopressors is that they prevent their own 
distribution in the circulatory system. 
 
Given that the survival rate to hospital discharge after cardiac arrest may be less than 
3% (Gueugniaud et al. 1998), there is great scope for improvement of current 
treatment protocols. One serious problem holding back progress in this field is a 
reluctance of physicians, for ethical reasons to participate in clinical trials, or to enter 
patients into trials when one arm of the trial constitutes a placebo, or a new drug not 
recommended in the guidelines (Woodhouse et al. 1995). This has led to many studies 
being underpowered. Taking into account the multitude of evidence that suggests that 
adrenaline is not beneficial during resuscitation, and the potential number of lives that 
could be saved by an improvement in resuscitation protocol, there is a strong 
argument that clinical trials in this field are ethical. This concern has been expressed 
by the 2005 International Consensus Conference on CPR “Further research is needed 
in virtually all facets of CPR… Ethics committees must empower investigators to 
challenge the unproven dogma that we have tolerated for far too long” (Nolan et al. 
2005). However, results with vasopressin have proved equivocal, and no other 
vasopressor agents have shown much promise to date. The onus is therefore on those 
involved in laboratory research to direct their work urgently to finding a beneficial 
alternative to adrenaline and to produce sufficient data to convince clinicians to 
participate in clinical trials.  
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10 Figures and Tables 
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Figure 1: Algorithm for Advanced Life Support. Modified from International Liaison Committee 
on Resuscitation (2005) 
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Figure 2. Pathophysiological factors involved in reperfusion injury. The overlap between the 
circles indicates the shared mechanisms between ischaemic damage and reperfusion injury. 
MPTP, mitochondrial permeability transition pore. 
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Figure 3: Ischaemia and reperfusion in the isolated right ventricle of the rat. A and B are 
representative traces from individual traces showing developed tension before, during and after 
simulated ischaemia (induced by removal of glucose from the bathing solution and gassing with 
95% N2 / 5% CO2 instead of 95% O2 / 5% CO2). In A, the tissue was untreated (control) whereas 
B shows a tissue treated with adrenaline (10-5 M) for the final five minutes of ischaemia and the 
first 15 minutes of reperfusion as a mimic of resuscitation. C shows mean results ± S.E.M (n=6). 
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Table 1: Cardiovascular effects of adrenoceptor subtypes in humans. The responses stated refer to actions on postsynaptic smooth 
muscle receptors unless otherwise stated in brackets. Where one receptor subtype appears to dominate functionally in a particular 
vascular bed, this is also indicated.  indicates potential beneficial effect during CPR  indicates potential detrimental effect during 
CPR. 
 
  Vascular Effects Cardiac effects 
Receptor 
Subtype 
Major 
Transduction 
Mechanism 
Large arteries Arterioles Veins Chronotropy Inotropy 
Α1A   Gq/11 Vasoconstriction - coronary arteries 
 
 
Vasoconstriction  
 
Vasoconstriction 
 
+ve  +ve  
Α1B Gq/11 Vasoconstriction  Vasoconstriction  Vasoconstriction 
 
+ve  +ve  
Α1D Gq/11 Vasoconstriction   Vasoconstriction     
Α2A Gi/o Vasoconstriction  
Vasodilatation (endothelium)  
Vasodilatation 
(endothelium)   
Vasoconstriction 
 
 -ve (pre- 
synaptic) 
  
Α2B Gi/o Vasoconstriction – coronary ?  Vasoconstriction    
Α2C Gi/o Prevents NA release (presynaptic)  Cold-induced 
vasoconstriction 
Vasoconstriction 
 
 -ve (pre- 
synaptic) 
 
Β1  Gs Vasodilatation - coronary arteries  Vasodilatation   +ve  +ve  
Β2 Gs Vasodilatation  Vasodilatation   +ve  +ve  
Β3 Gi/o Vasodilatation  Vasodilatation    -ve  
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